Kura Oncology Cash Flow Statement
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kura Oncology free cash flow
In fiscal 2025, Kura Oncology generated -$64.1 million of operating cash flow and spent $6.6 million on capital expenditures. That left free cash flow of -$70.7 million, a free-cash-flow margin of -104.8% of revenue. Free cash flow was down 152.8% from the prior year's $133.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Kura Oncology cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -278.67M | -173.98M | -152.63M | -135.84M | -130.47M | -89.63M | -63.14M | -60.45M | -35.43M | -27.56M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.03M | 848.00K | 849.00K | 759.00K | 558.00K | 194.00K | 0 | 10.00K | 30.00K | 31.00K |
| Stock-Based Compensation | 37.11M | 33.90M | 28.08M | 26.32M | 23.58M | 12.81M | 9.41M | 8.65M | 4.54M | 2.09M |
| Change in Working Capital | 177.11M | 267.64M | -2.88M | -3.74M | -2.88M | 4.97M | -19.00K | 4.65M | 2.86M | -32.00K |
| Operating Cash Flow | -64.06M | 134.32M | -124.82M | -110.06M | -104.55M | -69.83M | -54.76M | -48.66M | -28.44M | -25.35M |
| Capital Expenditures | -6.64M | -472.00K | -168.00K | -626.00K | -1.15M | -2.17M | — | — | — | — |
| Investing Cash Flow | -13.10M | -101.59M | 15.56M | 32.63M | -126.83M | -99.94M | -46.33M | -79.30M | -23.42M | 12.18M |
| Debt Issued | — | — | — | 10.00M | — | — | — | 627.00K | — | 7.45M |
| Debt Repaid | — | — | — | — | -7.25M | -250.00K | — | -1.25M | — | — |
| Financing Cash Flow | 1.79M | 154.42M | 94.78M | 38.56M | -3.44M | 469.33M | 111.10M | 132.64M | 53.57M | 7.45M |
| Net Change in Cash | -75.36M | 187.14M | -14.48M | -38.87M | -234.82M | 299.57M | 10.02M | 4.69M | 1.71M | -5.72M |
| Free Cash Flow | -70.70M | 133.84M | -124.99M | -110.69M | -105.70M | -72.00M | -54.76M | -48.66M | -28.44M | -25.35M |
This table shows 10 annual periods of Kura Oncology's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KURA's reporting calendar. What is a cash flow statement?